Multicenter Single Arm Phase II Study of Single Agent Palifosfamide in Recurrent and Incurable Germ Cell Tumors
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Palifosfamide (Primary)
- Indications Carcinoma; Germ cell and embryonal neoplasms; Germ cell cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Alaunos Therapeutics
- 01 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 01 Feb 2015 Planned End Date changed from 1 Sep 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 01 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.